Filed under: Investing It's safe to say that investors have been happy with Bristol-Myers Squibb in 2013. This big pharma powerhouse has jumped to gains of more than 55% on the year, outpacing its health care rivals by a ... FULL ARTICLE AT Daily Finance
The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts. This coordinated activity is essential for maintaining healthy bone. However, excessive osteoclast activity leads ... FULL ARTICLE AT News-Medical.net
GlaxoSmithKline is passing on two more ChemoCentryx Inc. drugs and closing out a seven-year drug development pact with the Mountain View company.
GSK (NYSE: GSK) declined an option to license CCX-168, an experimental treatment for a potentially fatal autoimmune inflammatory ... FULL ARTICLE AT San Francisco Business Times
Myriad Genetics Inc. is interested in buying molecular diagnostics test developer Crescendo Bioscience Inc. in an all-cash deal triggered by Crescendo hitting a minimum sales target for its Vectra DA rheumatoid arthritis test.
The genesis of the deal between Myriad ... FULL ARTICLE AT Business Journal of Jacksonville
Share this page
About this topic
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks synovial joints. The process produces an inflammatory response of the synovium (synovitis) secondary to hyperplasia of synovial cells, excess synovial fluid, and the development of pannus in the synovium. The pathology of the disease process often leads to the... Full Article At Wikipedia.org